Replies to post #62455 on Biotech Values

[microcapfun]

>>HGSI – Agree with your post on all counts. Moreover, HGSI’s “preference share” market research supposedly showed that most of the sampled docs who thought q4w dosing was a big deal also thought q2w dosing was a big deal; hence, these docs will be on board in any case if q2w works out on safety, efficacy, and tolerability.<<

I agree that q2w is likely to be sufficient for Albuferon to become the market leading IF alpha *if* it works out as you say, and if none of the other q2w IF alpha candidates do any better. (Albuferon is the 'first-mover' q2w IF alpha at this point.)

micro